Genital Herpes Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Genital Herpes pipeline constitutes 18+ key companies continuously working towards developing 20+ Genital Herpes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Genital Herpes Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Genital Herpes Market.

The Genital Herpes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Genital Herpes Pipeline Report: https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Genital Herpes treatment therapies with a considerable amount of success over the years.
• In April 2025, Initial clinical and preclinical data shared at the 35th ESCMID Global Conference in Vienna, Austria, indicate that Assembly Biosciences' ABI-5366-a novel helicase-primase inhibitor (HPI) targeting herpes simplex virus (HSV)-has the potential to reshape treatment for recurrent genital herpes (RGH). Designed for monthly or weekly oral dosing, ABI-5366 shows favorable pharmacokinetics, strong tissue penetration, and high potency at the nanomolar level against both HSV-1 and HSV-2. This candidate could overcome key challenges associated with nucleoside analogues, particularly issues related to treatment adherence and sustained therapeutic effect.
• Genital Herpes companies working in the treatment market are Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others, are developing therapies for the Genital Herpes treatment
• Emerging Genital Herpes therapies in the different phases of clinical trials are- Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others are expected to have a significant impact on the Genital Herpes market in the coming years.
• In May 2024, Sexual health company Wisp has extended its collaboration with TBD Health by providing access to TBD Health's sexually transmitted infection/disease (STI/STD) testing kits through its platform. Under the expanded partnership, Wisp telehealth patients can be referred to TBD Health's in-person clinics for STD testing, PrEP prescriptions, UTI treatments, and additional healthcare services.

Genital Herpes Overview
Genital herpes is a common STI caused by the herpes simplex virus (HSV), typically HSV-2, though HSV-1 can also cause it. It leads to painful blisters or sores in the genital or anal area, itching, and discomfort during urination. The infection is chronic and can recur, as the virus remains dormant in nerve cells. While there is no cure, antiviral medications can help manage symptoms, reduce outbreaks, and lower the risk of transmission.

Get a Free Sample PDF Report to know more about Genital Herpes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Genital Herpes Drugs Under Different Phases of Clinical Development Include:
• mRNA 1608: Moderna Therapeutics
• Attenuated vaccine against HSV 1&2: Vaxxit
• HSV "Genital lesions" Skin cream/Lotion: Nanoviricides
• BNT 163: BioNTech
• GSK 3943104A: GlaxoSmithKline
• UB 621: United BioPharma
• HDIT101: Heidelberg ImmunoTherapeutics
• Pritelivir: AiCuris

Genital Herpes Route of Administration
Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Genital Herpes Molecule Type
Genital Herpes Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Genital Herpes Pipeline Therapeutics Assessment
• Genital Herpes Assessment by Product Type
• Genital Herpes By Stage and Product Type
• Genital Herpes Assessment by Route of Administration
• Genital Herpes By Stage and Route of Administration
• Genital Herpes Assessment by Molecule Type
• Genital Herpes by Stage and Molecule Type

DelveInsight's Genital Herpes Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Genital Herpes product details are provided in the report. Download the Genital Herpes pipeline report to learn more about the emerging Genital Herpes therapies at:
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Genital Herpes Therapeutics Market include:
Key companies developing therapies for Genital Herpes are - AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others.

Genital Herpes Pipeline Analysis:
The Genital Herpes pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Genital Herpes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Herpes Treatment.
• Genital Herpes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Genital Herpes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Genital Herpes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Genital Herpes drugs and therapies-
https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Genital Herpes Pipeline Market Drivers
• Increasing awareness among the population regarding genital herpes infection, availability of high sensitivity and specificity of nucleic acid amplification based kits test type are some of the important factors that are fueling the Genital Herpes Market.

Genital Herpes Pipeline Market Barriers
• However, accessibility of diagnostic services, Insufficient R&D initiatives, pricing pressures, and stringent regulations, lack of novel strategies to prevent or suppress HSV-2 infection and other factors are creating obstacles in the Genital Herpes Market growth.

Scope of Genital Herpes Pipeline Drug Insight
• Coverage: Global
• Key Genital Herpes Companies: Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutics, AiCuris, and others
• Key Genital Herpes Therapies: Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others
• Genital Herpes Therapeutic Assessment: Genital Herpes current marketed and Genital Herpes emerging therapies
• Genital Herpes Market Dynamics: Genital Herpes market drivers and Genital Herpes market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.